Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy

This publication has 45 references indexed in Scilit:

• Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies
  European Journal of Cancer, 2017
• Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy
  Annals of Oncology, 2016
• Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy
  Annals of Oncology, 2016
• Predictors and survival in patients with melanoma brain metastases
  Medical Oncology, 2013
• Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma
  American Journal of Clinical Oncology, 2011
• Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studies
  Pharmaceutical Statistics, 2011
• Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial
  The Lancet Oncology, 2009
• Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases
  JAMA, 2006
• Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
  The Lancet, 2004
• Malignant melanoma and central nervous system metastases.Incidence, diagnosis, treatment and survival
  Cancer, 1978